WO2019103456A3 - Biomarker composition for diagnosing radiation-resistant cancer or for predicting prognosis of radiation therapy containing pmvk as active ingredient - Google Patents

Biomarker composition for diagnosing radiation-resistant cancer or for predicting prognosis of radiation therapy containing pmvk as active ingredient Download PDF

Info

Publication number
WO2019103456A3
WO2019103456A3 PCT/KR2018/014363 KR2018014363W WO2019103456A3 WO 2019103456 A3 WO2019103456 A3 WO 2019103456A3 KR 2018014363 W KR2018014363 W KR 2018014363W WO 2019103456 A3 WO2019103456 A3 WO 2019103456A3
Authority
WO
WIPO (PCT)
Prior art keywords
pmvk
radiation
active ingredient
diagnosing
resistant cancer
Prior art date
Application number
PCT/KR2018/014363
Other languages
French (fr)
Korean (ko)
Other versions
WO2019103456A2 (en
Inventor
최은경
정성윤
송시열
박윤용
박석순
주은진
고은정
Original Assignee
울산대학교 산학협력단
재단법인 아산사회복지재단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180143493A external-priority patent/KR102141997B1/en
Application filed by 울산대학교 산학협력단, 재단법인 아산사회복지재단 filed Critical 울산대학교 산학협력단
Priority to US16/766,297 priority Critical patent/US11674184B2/en
Priority to CN201880087275.XA priority patent/CN111630185A/en
Priority to EP18881259.8A priority patent/EP3715475A4/en
Priority to JP2020546259A priority patent/JP6924907B2/en
Publication of WO2019103456A2 publication Critical patent/WO2019103456A2/en
Publication of WO2019103456A3 publication Critical patent/WO2019103456A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a biomarker composition for diagnosing radiation-resistant cancer containing PMVK as an active ingredient, and a method for diagnosing radiation-resistant cancer using the same, wherein when the PMVK was knocked down, it was confirmed that the survival rate of cancer cells decreases in the radiation treatment, and on the basis of this, it was suggested that it is possible to use the PMVK as a radiation therapy resistance-related factor for cancer, whereby the PMVK can be utilized as a novel target that can enhance the radiation therapy effect on human cancer cells.
PCT/KR2018/014363 2017-11-22 2018-11-21 Biomarker composition for diagnosing radiation-resistant cancer or for predicting prognosis of radiation therapy containing pmvk as active ingredient WO2019103456A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US16/766,297 US11674184B2 (en) 2017-11-22 2018-11-21 Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA
CN201880087275.XA CN111630185A (en) 2017-11-22 2018-11-21 Biomarker composition for diagnosing radiation-resistant cancer or predicting prognosis of radiation therapy comprising PMVK as active ingredient
EP18881259.8A EP3715475A4 (en) 2017-11-22 2018-11-21 Biomarker composition for diagnosing radiation-resistant cancer or for predicting prognosis of radiation therapy containing pmvk as active ingredient
JP2020546259A JP6924907B2 (en) 2017-11-22 2018-11-21 Biomarker composition for diagnosing radiation-resistant cancer or predicting the prognosis of radiotherapy containing PMVK as an active ingredient

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0156320 2017-11-22
KR20170156320 2017-11-22
KR10-2018-0143493 2018-11-20
KR1020180143493A KR102141997B1 (en) 2017-11-22 2018-11-20 Biomarker composition for diagnosing radiation resistant cancer or predicting prognosis of radiation therapy comprising PMVK

Publications (2)

Publication Number Publication Date
WO2019103456A2 WO2019103456A2 (en) 2019-05-31
WO2019103456A3 true WO2019103456A3 (en) 2019-07-18

Family

ID=66632038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/014363 WO2019103456A2 (en) 2017-11-22 2018-11-21 Biomarker composition for diagnosing radiation-resistant cancer or for predicting prognosis of radiation therapy containing pmvk as active ingredient

Country Status (1)

Country Link
WO (1) WO2019103456A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112213492B (en) * 2019-07-09 2024-04-30 复旦大学 Application of CLIC4 in preparation of preparation for treating nasopharyngeal carcinoma by radiation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048414A1 (en) * 2008-05-09 2010-02-25 The Regents Of The University Of California A California Corporation Novel methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
US7939263B2 (en) * 2005-06-13 2011-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20110129822A1 (en) * 2009-12-01 2011-06-02 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
KR20170094165A (en) * 2014-12-23 2017-08-17 제넨테크, 인크. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939263B2 (en) * 2005-06-13 2011-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20100048414A1 (en) * 2008-05-09 2010-02-25 The Regents Of The University Of California A California Corporation Novel methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
US20110129822A1 (en) * 2009-12-01 2011-06-02 Precision Therapeutics, Inc. Multi drug response markers for breast cancer cells
KR20170094165A (en) * 2014-12-23 2017-08-17 제넨테크, 인크. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LLOYD, KATHERINE L: "Prediction of resistance to chemotherapy in ovarian cancer: a systematic review", BMC CANCER, vol. 15, 2015, pages 1 - 32, XP021219158 *
See also references of EP3715475A4 *

Also Published As

Publication number Publication date
WO2019103456A2 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
CA2956871C (en) Compounds active towards bromodomains
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
WO2016201450A3 (en) Cancer treatment and diagnosis
WO2016066744A3 (en) Gip agonist compounds and methods
WO2015173633A3 (en) Hdl therapy markers
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2015009726A3 (en) Medical uses of cd38 agonists
WO2015185875A3 (en) Antibody which is directed against galectin-9 and is an inhibitor of the suppressor activity of regulatory t lymphocytes
EP4183806A3 (en) Glycan-interacting compounds and methods of use
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
TW201625535A (en) Inhibitors of histone demethylases
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
MX2023009371A (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy.
WO2015200648A8 (en) Use of peptides that block metadherin-snd1 interaction as treatment for cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18881259

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020546259

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018881259

Country of ref document: EP

Effective date: 20200622